Showing 1 of 1 recruiting trials for “B-cell prolymphocytic leukemia”
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
👨⚕️ Sumithira Vasu, MD, Ohio State University Comprehensive Cancer Center📍 2 sites📅 Started Jun 2022View details ↗
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →